Skip to main content

Table 1 Baseline demographic variables of the cohort analysed

From: Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models

Characteristics Whole cohort (n=1202) Epratuzumab plus standard of care (n=792) Standard of care only (n=410)
Age group (years)    
 <35 348 (29.0%) 224 (28.3%) 124 (30.2%)
 35–55 664 (55.2%) 436 (55.1%) 228 (55.6%)
 >55 190 (15.8%) 132 (16.7%) 58 (14.2%)
Female 1131 (94.1%) 739 (93.3%) 392 (95.6%)
Disease duration (years) 5.58 (1.92, 12.7) 5.75 (1.92, 12.7) 5.46 (1.83, 11.9)
ACR/SLICC-DI 0 (0, 2) 0 (0, 2) 0 (0, 2)
SLEDAI-2K 10 (8, 12) 10 (8, 12) 10 (8, 12)
nBILAG-2004 score median (IQR) 20 (16, 24) 20 (16, 24) 20 (16, 24)
BILAG-2004 A or B system score    
 Constitutional 117 (9.73%) 74 (9.34%) 43 (10.5%)
 Mucocutaneous 990 (82.4%) 653 (82.5%) 337 (82.2%)
 Neuropsychiatric 50 (4.16%) 36 (4.55%) 14 (3.41%)
 Musculoskeletal 1126 (93.7%) 741 (93.6%) 385 (93.9%)
 Cardiorespiratory 132 (11.0%) 89 (11.2%) 43 (10.5%)
 Gastrointestinal 23 (1.91%) 13 (1.64%) 10 (2.44%)
 Ophthalmological 15 (1.25%) 10 (1.26%) 5 (1.22%)
 Renal 91 (7.57%) 62 (7.83%) 29 (7.07%)
 Haematological 12 (1.00%) 9 (1.14%) 3 (0.73%)
Serology    
 Anti-Ro 571 (48.2%) 373 (47.8%) 198 (49.0%)
 Anti-RNP 353 (29.8%) 235 (30.1%) 118 (29.2%)
 Anti-dsDNA 334 (28.2%) 211 (27.1%) 123 (30.4%)
 Anti-Smith (Sm) 311 (27.3%) 204 (26.2%) 107 (26.5%)
 Low C3 level 395 (33.4%) 257 (33.0%) 138 (34.2%)
 Low C4 level 482 (40.8%) 320 (41.1%) 162 (40.1%)
Baseline steroid use 1129 (93.9%) 757 (95.6%) 372 (90.7%)
Baseline steroid dose (mg/day) 10 (5, 15) 10 (5, 15) 10 (5, 15)
Concomitant therapy    
 Anti-malarial 884 (73.5%) 595 (75.1%) 289 (70.5%)
 Methotrexate 251 (20.9%) 165 (20.8%) 86 (21.0%)
 Leflunomide 37 (3.08%) 37 (3.08%) 37 (3.08%)
 Azathioprine 321 (26.7%) 321 (26.7%) 321 (26.7%)
 Mycophenolate mofetil 143 (11.9%) 88 (11.1%) 55 (13.4%)
Drop out from trial 385 (32.0%) 259 (32.7%) 126 (30.7%)
Withdrawal (lack of efficacy) 174 (14.5%) 115 (14.5%) 59 (14.4%)
Withdrawal (adverse events) 78 (6.49%) 52 (6.57%) 26 (6.34%)
  1. Values are n (%) or median (IQR) as appropriate